Nevertheless, the role of uric acid in hepatic steatosis and IR through NLRP3 inflammasome activation has already been described [52], and compounds targeting serum uric acid levels have been proposed as therapeutic approaches for nonalcoholic fatty liver disease treatment [53]. Here, NLRP3 is linked to Hepatic steatosis.